Mira Pharmaceuticals (MIRA)
Market Price (6/3/2026): $1.04 | Market Cap: $43.6 MilSector: Health Care | Industry: Pharmaceuticals
Mira Pharmaceuticals (MIRA)
Market Price (6/3/2026): $1.04Market Cap: $43.6 MilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -21%, 3Y Excs Rtn is -169% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.8 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -27% Key risksMIRA key risks include [1] substantial doubt about its ability to continue as a going concern, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -22% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -21%, 3Y Excs Rtn is -169% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -9.8 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -27% |
| Key risksMIRA key risks include [1] substantial doubt about its ability to continue as a going concern, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Mira Pharmaceuticals (MIRA) stock has lost about 20% since 2/28/2026 because of the following key factors:
1. Mira Pharmaceuticals issued a "going concern" warning, stating that its existing cash and cash equivalents of $4.82 million as of March 31, 2026, are insufficient to support operations for 12 months from the financial statement issuance date, necessitating additional financing.
2. The company continues to incur significant operating losses as a pre-revenue, clinical-stage entity, with a net loss of $1.15 million in Q1 2026, even though it narrowed from $1.78 million in the prior year. This sustained cash burn contributed to the decline in its cash reserves.
Show more
Stock Movement Drivers
Fundamental Drivers
The -18.1% change in MIRA stock from 2/28/2026 to 6/2/2026 was primarily driven by a -54.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282026 | 6022026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.27 | 1.04 | -18.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 19 | 42 | -54.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2026 to 6/2/2026| Return | Correlation | |
|---|---|---|
| MIRA | -18.1% | |
| Market (SPY) | 11.0% | 40.0% |
| Sector (XLV) | -8.2% | 25.7% |
Fundamental Drivers
The -29.7% change in MIRA stock from 11/30/2025 to 6/2/2026 was primarily driven by a -54.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 6022026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.48 | 1.04 | -29.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 19 | 42 | -54.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 6/2/2026| Return | Correlation | |
|---|---|---|
| MIRA | -29.7% | |
| Market (SPY) | 11.8% | 31.3% |
| Sector (XLV) | -6.4% | 14.5% |
Fundamental Drivers
The -23.0% change in MIRA stock from 5/31/2025 to 6/2/2026 was primarily driven by a -60.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312025 | 6022026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.35 | 1.04 | -23.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 17 | 42 | -60.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2025 to 6/2/2026| Return | Correlation | |
|---|---|---|
| MIRA | -23.0% | |
| Market (SPY) | 30.4% | 24.7% |
| Sector (XLV) | 12.3% | 13.8% |
Fundamental Drivers
nullnull
Market Drivers
5/31/2023 to 6/2/2026| Return | Correlation | |
|---|---|---|
| MIRA | ||
| Market (SPY) | 88.9% | 6.2% |
| Sector (XLV) | 20.4% | 4.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MIRA Return | - | - | -86% | 9% | 32% | -30% | -86% |
| Peers Return | -36% | 4% | -8% | -17% | 239% | 27% | 122% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| MIRA Win Rate | - | - | 20% | 33% | 50% | 33% | |
| Peers Win Rate | 43% | 57% | 43% | 48% | 67% | 50% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 67% | |
Max Drawdowns [4] | |||||||
| MIRA Max Drawdown | - | - | - | -80% | -46% | -39% | |
| Peers Max Drawdown | -50% | -53% | -41% | -48% | -44% | -18% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: AXSM, JAZZ, ATAI, NBIX, RLMD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/2/2026 (YTD)
How Low Can It Go
| Event | MIRA | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -30.8% | -18.8% |
| % Gain to Breakeven | 44.5% | 23.1% |
| Time to Breakeven | 23 days | 79 days |
In The Past
Mira Pharmaceuticals's stock fell -30.8% during the 2025 US Tariff Shock. Such a loss loss requires a 44.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MIRA | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -30.8% | -18.8% |
| % Gain to Breakeven | 44.5% | 23.1% |
| Time to Breakeven | 23 days | 79 days |
In The Past
Mira Pharmaceuticals's stock fell -30.8% during the 2025 US Tariff Shock. Such a loss loss requires a 44.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Mira Pharmaceuticals (MIRA)
AI Analysis | Feedback
Here are 1-2 brief analogies for Mira Pharmaceuticals:
The Jazz Pharmaceuticals (formerly GW Pharmaceuticals) of next-generation synthetic cannabinoid drugs.
An early-stage Eli Lilly focused on developing novel synthetic cannabinoid drugs for cognitive decline and pain.
AI Analysis | Feedback
- MIRA1a: An investigational synthetic THC analog being developed for the treatment of anxiety, cognitive decline associated with early-stage dementia, and chronic pain.
AI Analysis | Feedback
```htmlMira Pharmaceuticals (MIRA) is an early pre-clinical-stage pharmaceutical company. At this stage, the company is focused on the research and development of its drug candidate, MIRA1a, and has not yet undergone clinical trials or received FDA approval for commercialization.
Therefore, Mira Pharmaceuticals does not currently have any major customers for its drug products, as it is not yet selling MIRA1a to other companies or directly to individuals.
```AI Analysis | Feedback
nullAI Analysis | Feedback
Erez Aminov, Chairman of the Board and Chief Executive OfficerErez Aminov was appointed Chief Executive Officer in April 2023. He brings deep expertise in biotechnology consulting, investment, and leadership. Prior to joining MIRA Pharmaceuticals, he founded Locate Venture Corp, where he supported early-stage biotech enterprises and fostered growth through strategic partnerships. He has also served as a trusted consultant for multiple biotech firms and successfully guided two companies through IPOs on the Nasdaq. Additionally, he serves as the Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc..
Alan Weichselbaum, Chief Financial OfficerAlan Weichselbaum was appointed Chief Financial Officer effective May 15, 2025. He has over 30 years of experience in corporate finance, capital markets, and strategic advisory. He currently serves as CFO of both MIRA Pharmaceuticals, Inc. and Telomir Pharmaceuticals, Inc. Since 2015, he has been a Director of FinWise Bancorp. In 2011, Mr. Weichselbaum founded The Wexus Group, an outsourced CFO advisory firm. From 1995 to 2010, he held senior roles on Wall Street, including equity analyst, manager of two hedge funds, and CEO of a boutique brokerage firm. His career also includes managerial positions at Philip Morris Capital Corporation and Price Waterhouse.
Adam Kaplin, Co-Founder, President & Chief Science OfficerDr. Adam Kaplin co-founded MIRA Pharmaceuticals, Inc. in 2020. He is a neuropsychiatrist specializing in the biological basis of immune-mediated depression and cognitive impairment. Previously, he served as the chief neuropsychiatric consultant to the Johns Hopkins Multiple Sclerosis Center of Excellence and was the founder and director of the Johns Hopkins Ketamine Clinic. He has also co-founded other healthcare-related startups, including REWARD Pathways, focused on addiction treatment.
Itzchak Angel, Chief Scientific AdvisorDr. Itzchak Angel is an accomplished executive with over 40 years of experience in the pharmaceutical industry, guiding medical, pharmaceutical, drug, and business development. Since 2005, he has been President and CEO of Angel Pharmaceutical Consulting & Technologies (A.P.C.T.), assisting various companies in drug development. He previously served as Head of Pharmacology at Synthelabo (now Sanofi-Aventis), where he contributed to the research and development of drugs such as Xatral, Ambien, and Mizollen.
Ned MacPherson, DirectorNed MacPherson currently serves as Chief Growth Officer for Power Digital. From May 2016 to December 2023, he was the CEO and Head of Growth for Endrock Growth & Analytics, a company he founded and subsequently sold to Power Digital. Prior to founding Endrock Growth & Analytics, Mr. MacPherson held senior marketing and leadership positions at companies including sunglass maker Prive Revaux, curated meal company Menud, and Rejuvenetics, LLC.
AI Analysis | Feedback
```htmlThe primary key risk to Mira Pharmaceuticals is the inherent uncertainty and extensive process of developing its sole drug candidate, MIRA1a, from an early pre-clinical stage through clinical trials to gain regulatory approval. The company's future success is entirely dependent on the successful development, FDA approval, and commercialization of MIRA1a, which faces significant hurdles given that current data is based on pre-clinical and animal studies and does not guarantee success in human trials or eventual market approval.
```AI Analysis | Feedback
```html null ```AI Analysis | Feedback
Mira Pharmaceuticals (MIRA) is developing MIRA1a for the treatment of anxiety, cognitive decline typically associated with early-stage dementia, and chronic pain. The addressable markets for these indications are substantial:
- Anxiety Treatment Market: The global anxiety disorders treatment market is estimated to be approximately USD 11.59 billion in 2024, with projections indicating growth to around USD 15.90 billion by 2032. Another estimate places the global anxiety disorders treatment market at USD 12.33 billion in 2025, expected to reach USD 17.56 billion by 2035. North America held a significant share of the global market in 2025.
- Cognitive Decline (Early-Stage Dementia) Treatment Market: The global dementia treatment market was estimated at USD 18.03 billion in 2024 and is projected to reach USD 28.11 billion by 2030. Similarly, the global dementia treatment market size was valued at USD 19.98 billion in 2025 and is expected to reach USD 38.37 billion by 2033. The U.S. dementia treatment market alone was approximately USD 6,261.6 million in 2024 and is expected to grow to USD 9,290.6 million by 2030. North America consistently holds a significant share of the global market.
- Chronic Pain Treatment Market: The global chronic pain treatment market was valued at approximately USD 84.23 billion in 2024 and is expected to reach USD 132.08 billion by 2030. Other estimates suggest the global market was around USD 90.73 billion in 2024 and is anticipated to reach USD 152.42 billion by 2032. North America represents a significant portion of this market, with one report indicating it held approximately 45% market share in 2024. The U.S. chronic pain management market was valued at USD 31.18 billion in 2025 and is projected to reach USD 42.87 billion by 2034.
AI Analysis | Feedback
Mira Pharmaceuticals (MIRA) is an early clinical-stage pharmaceutical company, and as such, it currently generates no revenue from product sales. Its future revenue growth over the next 2-3 years will primarily be driven by key developmental and strategic milestones for its drug candidates, rather than immediate product sales. Analysts generally lack sufficient data to forecast traditional revenue growth for the company at this stage. The expected drivers of future revenue growth for Mira Pharmaceuticals over the next 2-3 years include: * Progression of Ketamir-2 through clinical trials: Ketamir-2, an oral ketamine analog, has successfully completed the Single Ascending Dose (SAD) portion of its Phase 1 clinical trial and is currently advancing into the Multiple Ascending Dose (MAD) stage. The company has also identified chemotherapy-induced peripheral neuropathy (CIPN) as the lead indication for a planned Phase 2a clinical evaluation, with an intent to submit the protocol by year-end 2025. Successful advancement through these clinical trial phases would significantly de-risk the asset, enhance its valuation, and pave the way for potential commercialization or partnerships, thereby driving future revenue. * Advancement of MIRA-55 into clinical trials: MIRA-55 (formerly MIRA1a), a synthetic THC analog, is in preclinical development for treating anxiety, cognitive decline, and chronic pain. A critical driver of future revenue potential will be the successful completion of preclinical studies and the filing of an Investigational New Drug (IND) application with the FDA, leading to the initiation of Phase 1 human clinical trials. Notably, the U.S. Drug Enforcement Administration (DEA) has determined that MIRA-55 is not a controlled substance, which could streamline its development and market access. * Formation of strategic partnerships and licensing agreements: Given the substantial capital and resources required for drug development, securing strategic partnerships or licensing agreements for either Ketamir-2 or MIRA-55 would be a significant revenue driver. Such agreements could provide upfront payments, milestone payments tied to development progress, and future royalties, offering non-dilutive funding and leveraging the development and commercialization expertise of larger pharmaceutical companies.AI Analysis | Feedback
Share Issuance
- Mira Pharmaceuticals completed an initial public offering (IPO) in August 2023, pricing 1,275,000 shares of common stock at $7.00 per share, which generated aggregate gross proceeds of $8.9 million.
- In October 2025, the company raised approximately $3,835,485 in gross proceeds by selling 1,751,000 shares of common stock through at-the-market (ATM) block sales to institutional investors at an average price of $2.19 per share.
- The company also financed operations through a private placement of common stock during the fourth quarter of 2021 and throughout 2022.
Inbound Investments
- As part of the acquisition of SKNY Pharmaceuticals in September 2025, SKNY contributed $5 million in marketable securities to Mira Pharmaceuticals, which strengthened MIRA's balance sheet.
- Institutional investors purchased a total of 382,371 shares of MIRA Pharmaceuticals' stock over the two years leading up to February 2026, representing approximately $502.42K in transactions.
Outbound Investments
- Mira Pharmaceuticals completed the acquisition of 100% of SKNY Pharmaceuticals, Inc. in September 2025, in an all-stock transaction. This acquisition expanded MIRA's pipeline to include therapeutic programs such as SKNY-1 for obesity and smoking cessation.
Capital Expenditures
- Information from financial statements, including cash flow statements, indicates that capital expenditures have been consistently reported as "N/A". This is typical for an early-stage biopharmaceutical company primarily focused on research and development activities.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 80.63 |
| Mkt Cap | 6.5 |
| Rev LTM | 356 |
| Op Inc LTM | -35 |
| FCF LTM | -24 |
| FCF 3Y Avg | -27 |
| CFO LTM | -24 |
| CFO 3Y Avg | -27 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 46.2% |
| Rev Chg 3Y Avg | 47.3% |
| Rev Chg Q | 30.7% |
| QoQ Delta Rev Chg LTM | 6.2% |
| Op Inc Chg LTM | 25.0% |
| Op Inc Chg 3Y Avg | 11.7% |
| Op Mgn LTM | -2.2% |
| Op Mgn 3Y Avg | -21.4% |
| QoQ Delta Op Mgn LTM | 2.5% |
| CFO/Rev LTM | 8.9% |
| CFO/Rev 3Y Avg | -5.3% |
| FCF/Rev LTM | 7.9% |
| FCF/Rev 3Y Avg | -6.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 6.5 |
| P/S | 10.5 |
| P/Op Inc | -6.8 |
| P/EBIT | -6.8 |
| P/E | -3.5 |
| P/CFO | -11.6 |
| Total Yield | -6.1% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -13.1% |
| D/E | 0.0 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 9.6% |
| 3M Rtn | 25.7% |
| 6M Rtn | 30.0% |
| 12M Rtn | 99.8% |
| 3Y Rtn | 101.5% |
| 1M Excs Rtn | 4.3% |
| 3M Excs Rtn | 14.1% |
| 6M Excs Rtn | 14.8% |
| 12M Excs Rtn | 80.0% |
| 3Y Excs Rtn | 18.4% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Development and commercialization of pharmaceuticals targeting neurologic and neuropsychiatric | 0 | 0 | ||
| Total | 0 | 0 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Development and commercialization of pharmaceuticals targeting neurologic and neuropsychiatric | -8 | |||
| Total | -8 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Development and commercialization of pharmaceuticals targeting neurologic and neuropsychiatric | -8 | |||
| Total | -8 |
| $ Mil | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Development and commercialization of pharmaceuticals targeting neurologic and neuropsychiatric | 5 | 1 | 3 | |
| Total | 5 | 1 | 3 |
Price Behavior
| Market Price | $1.04 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 08/03/2023 | |
| Distance from 52W High | -48.5% | |
| 50 Days | 200 Days | |
| DMA Price | $1.04 | $1.30 |
| DMA Trend | down | down |
| Distance from DMA | 0.5% | -19.8% |
| 3M | 1YR | |
| Volatility | 82.8% | 79.9% |
| Downside Capture | 224.06 | 191.06 |
| Upside Capture | 68.26 | 97.38 |
| Correlation (SPY) | 39.6% | 24.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.11 | 0.32 | 2.32 | 1.71 | 1.67 | -0.30 |
| Up Beta | -0.46 | 1.13 | 2.98 | 2.59 | 2.12 | -1.75 |
| Down Beta | 9.53 | 7.64 | 4.23 | 1.98 | 1.67 | 0.18 |
| Up Capture | -174% | -50% | 80% | 63% | 117% | 101% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 8 | 18 | 24 | 48 | 106 | 282 |
| Down Capture | -650% | -246% | 212% | 169% | 157% | 113% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 11 | 21 | 34 | 65 | 127 | 392 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MIRA | |
|---|---|---|---|---|
| MIRA | -17.0% | 79.6% | 0.08 | - |
| Sector ETF (XLV) | 12.4% | 14.6% | 0.58 | 13.3% |
| Equity (SPY) | 30.5% | 11.8% | 1.95 | 24.3% |
| Gold (GLD) | 35.9% | 26.7% | 1.12 | 7.0% |
| Commodities (DBC) | 44.5% | 18.9% | 1.81 | -11.0% |
| Real Estate (VNQ) | 10.1% | 13.2% | 0.47 | 17.7% |
| Bitcoin (BTCUSD) | -32.2% | 41.6% | -0.82 | 16.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MIRA | |
|---|---|---|---|---|
| MIRA | -31.5% | 396.8% | 0.41 | - |
| Sector ETF (XLV) | 5.0% | 14.7% | 0.16 | 4.7% |
| Equity (SPY) | 14.2% | 17.0% | 0.66 | 6.2% |
| Gold (GLD) | 18.3% | 18.0% | 0.83 | 1.2% |
| Commodities (DBC) | 10.4% | 19.4% | 0.42 | 0.7% |
| Real Estate (VNQ) | 2.9% | 18.8% | 0.06 | 6.3% |
| Bitcoin (BTCUSD) | 13.0% | 54.6% | 0.43 | 4.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MIRA | |
|---|---|---|---|---|
| MIRA | -17.2% | 396.8% | 0.41 | - |
| Sector ETF (XLV) | 9.6% | 16.5% | 0.47 | 4.7% |
| Equity (SPY) | 15.9% | 17.9% | 0.76 | 6.2% |
| Gold (GLD) | 13.2% | 16.0% | 0.68 | 1.2% |
| Commodities (DBC) | 7.5% | 17.9% | 0.34 | 0.7% |
| Real Estate (VNQ) | 5.5% | 20.7% | 0.23 | 6.3% |
| Bitcoin (BTCUSD) | 66.0% | 66.9% | 1.05 | 4.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/14/2026 | 10-Q |
| 12/31/2025 | 03/31/2026 | 10-K |
| 09/30/2025 | 11/13/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/28/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 09/15/2023 | 10-Q |
| 03/31/2023 | 08/04/2023 | 424B4 |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Pharmaceuticals Resources |
| Fierce Pharma |
| Pharm Exec |
| Endpoints News |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.